Subarachnoid hemorrhage(SAH)is a major subtype of stroke,characterized by high mortality and disability rates.Pyroptosis,a form of programmed cell death,has been identified as a key pathological process in early brain injury.Current research indicates that pyroptosis can occur in neurons,microglia,astrocytes,and cerebral vascular endothelial cells after SAH,leading to neurological dysfunction,brain edema,and disruption of the blood-brain barrier.The NOD-like receptor protein 3(NLRP3)inflammasome is regarded as a central regulatory component of pyroptosis,and its activation mechanisms and roles in various cell types have become focal points of research.A variety of therapeutic strategies targeting this pathway have emerged,including NLRP3 inhibitors,Caspase-1 inhibitors,and Gasdermin-D inhibitors.The aforemenetioned approaches all have demonstrated efficacy in animal studies.Additionally,novel technologies such as stem cell therapy,exosome therapy,and gas therapy offer novel intervention approaches for modulating pyroptosis.Although,various therapeutic strategies targeting pyroptosis-related pathways have emerged in recent years,a comprehensive summary remains absent.This article reviewed the advancements in pyroptosis research following SAH and associated treatment strategies,aiming to provide a theoretical foundation for subsequent mechanistic studies and clinical translation.

Objective:To evaluate the efficacy and safety of intrasaccular flow disruptor in wide-necked intracranial aneurysms.Methods:One hundred and seventeen patients with wide-necked intracranial aneurysms treated with intrasaccular flow disruptor were collected from Department of Neurointervention (First Affiliated Hospital of Zhengzhou University), Department of Neurosurgery (Beijing Tiantan Hospital, Capital Medical University), Department of Cerebrovascular Surgery, Neurosurgery Center (Zhujiang Hospital, Southern Medical University), and Department of Neurosurgery (First Affiliated Hospital of Harbin Medical University) from August 2022 to March 2024. Raymond-Roy Occlusion Classification (RROC) was employed to evaluate aneurysm embolization immediately after procedure; cranial CT or MRI within 48 hours of embolization were performed to identify any new intracranial hemorrhage, subarachnoid hemorrhage, or new symptomatic cerebral infarction related to the intracranial aneurysms. Modified Rankin Scale (mRS) was used to assess the neurological function at discharge. Imaging follow-up and outpatient follow-up were performed at 6 months after embolization to evaluate the aneurysm occlusion degree and complications.Results:A total of 117 intrasaccular flow disruptors were implanted in 117 patients, with a technical success rate of 100%; 115 patients (98.3%) enjoyed successful one-time release of their disruptors, and 2 patients (1.7%) required retrieval and redirection of the disruptors before second successful attempt. Flow disruptor plus stent was performed in 13 patients (11.1%). Immediately after procedure, RROC grading I was noted in 3 patients, grading II in 51 patients and grading III in 63 patients. Cranial CT or MRI within 48 hours of embolization indicated no new intracranial hemorrhage, subarachnoid hemorrhage, or symptomatic cerebral infarction related to the intracranial aneurysms. All patients had mRS score of 0 at discharge. Eighty-three patients completed a 6-month follow-up (RROC grading I in 41 patients, grading II in 33 patients and grading III in 9 patients), without ischemic or hemorrhagic adverse events.Conclusion:The results of this study preliminarily suggest that intrasaccular flow disruptor is effective and safe in wide-necked intracranial aneurysms.

Objective:To evaluate the efficacy and safety of Neuroform Atlas stent-assisted coil embolization in patients with middle cerebral artery bifurcation aneurysms.Methods:A retrospective analysis was performed; the clinical data of 46 patients with middle cerebral artery bifurcation aneurysms accepted Neuroform Atlas stent-assisted coil embolization in First Affiliated Hospital of Zhengzhou University, Beijing Tiantan Hospital Affiliated to Capital Medical University, First Affiliated Hospital of Harbin Medical University, Zhujiang Hospital of Southern Medical University and First Affiliated Hospital of Chongqing Medical University from January 2022 to March 2024 were collected. There were 28 ruptured aneurysms (60.87%) and 18 unruptured aneurysms (39.13%). Follow-up was performed for more than 3 months; Raymond-Roy grading was used to evaluate the aneurysm embolization immediately after embolization and during follow-up; perioperative hemorrhagic or ischemic complications were recorded; modified Rankin Scale (mRS) was used to evaluate the prognosis of the patients at discharge and during follow-up (mRS score≤2: good prognosis, and mRS score>2: poor prognosis).Results:Coil embolization was successful in all 46 patients. DSA immediately after embolization showed that 41 patients (89.13%) had completely occluded aneurysms (Raymond-Roy grading I), 2 patients (4.35%) had residual aneurysm neck (Raymond-Roy grading Ⅱ) and 3 patients (6.52%) had partially occluded aneurysms (Raymond-Roy grading Ⅲ). Perioperative complications occurred in 5 patients, including 2 with postoperative cerebral infarction, 1 with hydrocephalus, 1 with postoperative pneumonia leading to respiratory failure, and 1 with stent thrombosis during embolization. Both at discharge and 3 months after embolization, 43 patients (93.48%) had good prognosis and 3 patients (6.52%) had poor prognosis. No obvious ischemic complications (such as stent restenosis) or hemorrhagic complications (such as re-rupture of the aneurysms) were found in all patients. Thirty patients (65.22%) had imaging follow-up for 6-12 months: 26 (86.67%) had Raymond-Roy grading I, 3 (10.00%) had Raymond-Roy grading II, and 1 (3.33%) had Raymond-Roy grading III.Conclusion:Neuroform Atlas stent-assisted coil embolization has good short-term efficacy and high safety in middle cerebral artery bifurcation aneurysms, but long-term follow-up observation is still needed to verify its efficacy.

At present, acute brain injuries such as stroke and traumatic brain injury have become a serious burden on public health due to relatively limited treatment methods. As an emerging three-dimensional cell culture model, cerebral organoid can well redisplay the cellular diversity, tissue structure and functional characteristics of the human brain, providing an ideal platform for disease modeling, drug development and regenerative medicine research of acute brain injury. However, the construction and application of cerebral organoid are still in the exploratory stage at present, facing major technical bottlenecks such as insufficient vascularization, lack of immune microenvironment and tissue heterogeneity. This review summarizes the cultivation technique of cerebral organoid, highlights its application in acute brain injury, and analyzes its current technical bottleneck, so as to provide more reference basis for the development and application of this technology.

Subarachnoid hemorrhage(SAH)is a major subtype of stroke,characterized by high mortality and disability rates.Pyroptosis,a form of programmed cell death,has been identified as a key pathological process in early brain injury.Current research indicates that pyroptosis can occur in neurons,microglia,astrocytes,and cerebral vascular endothelial cells after SAH,leading to neurological dysfunction,brain edema,and disruption of the blood-brain barrier.The NOD-like receptor protein 3(NLRP3)inflammasome is regarded as a central regulatory component of pyroptosis,and its activation mechanisms and roles in various cell types have become focal points of research.A variety of therapeutic strategies targeting this pathway have emerged,including NLRP3 inhibitors,Caspase-1 inhibitors,and Gasdermin-D inhibitors.The aforemenetioned approaches all have demonstrated efficacy in animal studies.Additionally,novel technologies such as stem cell therapy,exosome therapy,and gas therapy offer novel intervention approaches for modulating pyroptosis.Although,various therapeutic strategies targeting pyroptosis-related pathways have emerged in recent years,a comprehensive summary remains absent.This article reviewed the advancements in pyroptosis research following SAH and associated treatment strategies,aiming to provide a theoretical foundation for subsequent mechanistic studies and clinical translation.

Objective:To evaluate the efficacy and safety of intrasaccular flow disruptor in wide-necked intracranial aneurysms.Methods:One hundred and seventeen patients with wide-necked intracranial aneurysms treated with intrasaccular flow disruptor were collected from Department of Neurointervention (First Affiliated Hospital of Zhengzhou University), Department of Neurosurgery (Beijing Tiantan Hospital, Capital Medical University), Department of Cerebrovascular Surgery, Neurosurgery Center (Zhujiang Hospital, Southern Medical University), and Department of Neurosurgery (First Affiliated Hospital of Harbin Medical University) from August 2022 to March 2024. Raymond-Roy Occlusion Classification (RROC) was employed to evaluate aneurysm embolization immediately after procedure; cranial CT or MRI within 48 hours of embolization were performed to identify any new intracranial hemorrhage, subarachnoid hemorrhage, or new symptomatic cerebral infarction related to the intracranial aneurysms. Modified Rankin Scale (mRS) was used to assess the neurological function at discharge. Imaging follow-up and outpatient follow-up were performed at 6 months after embolization to evaluate the aneurysm occlusion degree and complications.Results:A total of 117 intrasaccular flow disruptors were implanted in 117 patients, with a technical success rate of 100%; 115 patients (98.3%) enjoyed successful one-time release of their disruptors, and 2 patients (1.7%) required retrieval and redirection of the disruptors before second successful attempt. Flow disruptor plus stent was performed in 13 patients (11.1%). Immediately after procedure, RROC grading I was noted in 3 patients, grading II in 51 patients and grading III in 63 patients. Cranial CT or MRI within 48 hours of embolization indicated no new intracranial hemorrhage, subarachnoid hemorrhage, or symptomatic cerebral infarction related to the intracranial aneurysms. All patients had mRS score of 0 at discharge. Eighty-three patients completed a 6-month follow-up (RROC grading I in 41 patients, grading II in 33 patients and grading III in 9 patients), without ischemic or hemorrhagic adverse events.Conclusion:The results of this study preliminarily suggest that intrasaccular flow disruptor is effective and safe in wide-necked intracranial aneurysms.

Objective:To evaluate the efficacy and safety of Neuroform Atlas stent-assisted coil embolization in patients with middle cerebral artery bifurcation aneurysms.Methods:A retrospective analysis was performed; the clinical data of 46 patients with middle cerebral artery bifurcation aneurysms accepted Neuroform Atlas stent-assisted coil embolization in First Affiliated Hospital of Zhengzhou University, Beijing Tiantan Hospital Affiliated to Capital Medical University, First Affiliated Hospital of Harbin Medical University, Zhujiang Hospital of Southern Medical University and First Affiliated Hospital of Chongqing Medical University from January 2022 to March 2024 were collected. There were 28 ruptured aneurysms (60.87%) and 18 unruptured aneurysms (39.13%). Follow-up was performed for more than 3 months; Raymond-Roy grading was used to evaluate the aneurysm embolization immediately after embolization and during follow-up; perioperative hemorrhagic or ischemic complications were recorded; modified Rankin Scale (mRS) was used to evaluate the prognosis of the patients at discharge and during follow-up (mRS score≤2: good prognosis, and mRS score>2: poor prognosis).Results:Coil embolization was successful in all 46 patients. DSA immediately after embolization showed that 41 patients (89.13%) had completely occluded aneurysms (Raymond-Roy grading I), 2 patients (4.35%) had residual aneurysm neck (Raymond-Roy grading Ⅱ) and 3 patients (6.52%) had partially occluded aneurysms (Raymond-Roy grading Ⅲ). Perioperative complications occurred in 5 patients, including 2 with postoperative cerebral infarction, 1 with hydrocephalus, 1 with postoperative pneumonia leading to respiratory failure, and 1 with stent thrombosis during embolization. Both at discharge and 3 months after embolization, 43 patients (93.48%) had good prognosis and 3 patients (6.52%) had poor prognosis. No obvious ischemic complications (such as stent restenosis) or hemorrhagic complications (such as re-rupture of the aneurysms) were found in all patients. Thirty patients (65.22%) had imaging follow-up for 6-12 months: 26 (86.67%) had Raymond-Roy grading I, 3 (10.00%) had Raymond-Roy grading II, and 1 (3.33%) had Raymond-Roy grading III.Conclusion:Neuroform Atlas stent-assisted coil embolization has good short-term efficacy and high safety in middle cerebral artery bifurcation aneurysms, but long-term follow-up observation is still needed to verify its efficacy.

At present, acute brain injuries such as stroke and traumatic brain injury have become a serious burden on public health due to relatively limited treatment methods. As an emerging three-dimensional cell culture model, cerebral organoid can well redisplay the cellular diversity, tissue structure and functional characteristics of the human brain, providing an ideal platform for disease modeling, drug development and regenerative medicine research of acute brain injury. However, the construction and application of cerebral organoid are still in the exploratory stage at present, facing major technical bottlenecks such as insufficient vascularization, lack of immune microenvironment and tissue heterogeneity. This review summarizes the cultivation technique of cerebral organoid, highlights its application in acute brain injury, and analyzes its current technical bottleneck, so as to provide more reference basis for the development and application of this technology.

Moyamoya disease is a relatively rare cerebrovascular disease. Extracranial and intracranial vascular bypass is the first choice for moyamoya disease. However, due to the risk of complications and symptoms recurrence after surgery, there is still some controversy about surgical treatment. In recent years, with the development of minimally invasive interventional technology, the endovascular treatment of atherosclerotic ischemic cerebrovascular disease has been widely carried out in the world. Some doctors are also beginning to try endovascular treatment of ischemic moyamoya disease, but its efficacy and safety are still unclear. This article reviews the endovascular treatment of ischemic moyamoya disease.

Clinically,arteriovenous malformations (AVM) is a common intracranial vascular disease.Traditional treatments for cerebral AVM include microsurgical resection,endovascular embolization and radiotherapy.However,there are some unusual AVM lesions that are difficult to be cured by traditional methods.Multiple case reports that have been published recently indicate that embolization therapy via transvenous approach is very effective for these unusual AVM lesions,especially for small hemorrhagic AVMs.These lesions often have single vein drainage and are located at deep cerebral function area.with their blood supply being from fine arteries.This paper aims to review the existing literature and to make a summary about the indications,method of operation,risks and prevention,etc.of embolization therapy via transvenous approach for cerebral AVM.